The global Oral Factor Xa Inhibitors market was valued at US$ 21480 million in 2023 and is anticipated to reach US$ 32310 million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.

Oral Factor Xa Inhibitors Market

Oral Factor Xa inhibitors are a class of anticoagulant medications that prevent blood clot formation by directly blocking Factor Xa, an enzyme crucial to the clotting process. Taken orally, these drugs are used to manage and prevent conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF).Key examples include rivaroxaban, apixaban, and edoxaban.

The market for oral Factor Xa inhibitors has been expanding due to their advantages over traditional anticoagulants. Drugs such as rivaroxaban, apixaban, and edoxaban are increasingly favored for their ease of use, fixed dosing, and reduced need for monitoring, leading to their widespread adoption for managing conditions like deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF).

Innovation and competition are driving the market, with pharmaceutical companies focusing on developing new formulations and extended-release versions. These advancements aim to enhance efficacy, safety profiles, and patient convenience. The growing range of options is contributing to a more dynamic market, offering healthcare providers more choices for anticoagulant therapy.

Despite the growth, the market faces challenges such as high costs and the introduction of alternative therapies. Regulatory changes and evolving treatment guidelines can also impact market trends. However, ongoing research and development are likely to sustain market momentum, as new drug options and improved formulations continue to emerge.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Oral Factor Xa Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Factor Xa Inhibitors.

The Oral Factor Xa Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Oral Factor Xa Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Oral Factor Xa Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Oral Factor Xa Inhibitors Market Report

Report Metric	Details
Report Name	Oral Factor Xa Inhibitors Market
Accounted market size in 2023	US$ 21480 million
Forecasted market size in 2030	US$ 32310 million
CAGR	6.0%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Rivaroxaban Edoxaban Apixaban
Segment by Application	Deep Vein Thrombosis Pulmonary Embolism Atrial Fibrillation Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Pfizer, Bristol Myers Squibb, Daiichi Sankyo, Janssen Pharmaceuticals, Bayer, Mylan, Zydus, Lupin, Apotex, Accord Healthcare, Chia Tai Tianqing Pharmaceutical, Shanghai Huilun Pharmaceutical, Qilu Pharmaceutical, HEC Pharma, Cspc Ouyi Pharmaceutical, Zhejiang Hisun Pharmaceutical, Hansoh Pharma, Huahai Pharmaceutical, Yangtze River Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oral Factor Xa Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oral Factor Xa Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Oral Factor Xa Inhibitors Market growing?

Ans: The Oral Factor Xa Inhibitors Market witnessing a CAGR of 6.0% during the forecast period 2024-2030.

What is the Oral Factor Xa Inhibitors Market size in 2030?

Ans: The Oral Factor Xa Inhibitors Market size in 2030 will be US$ 32310 million.

Who are the main players in the Oral Factor Xa Inhibitors Market report?

Ans: The main players in the Oral Factor Xa Inhibitors Market are Pfizer, Bristol Myers Squibb, Daiichi Sankyo, Janssen Pharmaceuticals, Bayer, Mylan, Zydus, Lupin, Apotex, Accord Healthcare, Chia Tai Tianqing Pharmaceutical, Shanghai Huilun Pharmaceutical, Qilu Pharmaceutical, HEC Pharma, Cspc Ouyi Pharmaceutical, Zhejiang Hisun Pharmaceutical, Hansoh Pharma, Huahai Pharmaceutical, Yangtze River Pharmaceutical

What are the Application segmentation covered in the Oral Factor Xa Inhibitors Market report?

Ans: The Applications covered in the Oral Factor Xa Inhibitors Market report are Deep Vein Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Other

What are the Type segmentation covered in the Oral Factor Xa Inhibitors Market report?

Ans: The Types covered in the Oral Factor Xa Inhibitors Market report are Rivaroxaban, Edoxaban, Apixaban

1 Oral Factor Xa Inhibitors Market Overview

1.1 Product Definition

1.2 Oral Factor Xa Inhibitors by Type

1.2.1 Global Oral Factor Xa Inhibitors Market Value Comparison by Type (2024-2030)

1.2.2 Rivaroxaban

1.2.3 Edoxaban

1.2.4 Apixaban

1.3 Oral Factor Xa Inhibitors by Application

1.3.1 Global Oral Factor Xa Inhibitors Market Value by Application (2024-2030)

1.3.2 Deep Vein Thrombosis

1.3.3 Pulmonary Embolism

1.3.4 Atrial Fibrillation

1.3.5 Other

1.4 Global Oral Factor Xa Inhibitors Market Size Estimates and Forecasts

1.4.1 Global Oral Factor Xa Inhibitors Revenue 2019-2030

1.4.2 Global Oral Factor Xa Inhibitors Sales 2019-2030

1.4.3 Global Oral Factor Xa Inhibitors Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Oral Factor Xa Inhibitors Market Competition by Manufacturers

2.1 Global Oral Factor Xa Inhibitors Sales Market Share by Manufacturers (2019-2024)

2.2 Global Oral Factor Xa Inhibitors Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Oral Factor Xa Inhibitors Average Price by Manufacturers (2019-2024)

2.4 Global Key Players of Oral Factor Xa Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Oral Factor Xa Inhibitors, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Oral Factor Xa Inhibitors, Product Type & Application

2.7 Global Key Manufacturers of Oral Factor Xa Inhibitors, Date of Enter into This Industry

2.8 Global Oral Factor Xa Inhibitors Market Competitive Situation and Trends

2.8.1 Global Oral Factor Xa Inhibitors Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Oral Factor Xa Inhibitors Players Market Share by Revenue

2.8.3 Global Oral Factor Xa Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Oral Factor Xa Inhibitors Market Scenario by Region

3.1 Global Oral Factor Xa Inhibitors Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Oral Factor Xa Inhibitors Sales by Region: 2019-2030

3.2.1 Global Oral Factor Xa Inhibitors Sales by Region: 2019-2024

3.2.2 Global Oral Factor Xa Inhibitors Sales by Region: 2025-2030

3.3 Global Oral Factor Xa Inhibitors Revenue by Region: 2019-2030

3.3.1 Global Oral Factor Xa Inhibitors Revenue by Region: 2019-2024

3.3.2 Global Oral Factor Xa Inhibitors Revenue by Region: 2025-2030

3.4 North America Oral Factor Xa Inhibitors Market Facts & Figures by Country

3.4.1 North America Oral Factor Xa Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Oral Factor Xa Inhibitors Sales by Country (2019-2030)

3.4.3 North America Oral Factor Xa Inhibitors Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Oral Factor Xa Inhibitors Market Facts & Figures by Country

3.5.1 Europe Oral Factor Xa Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Oral Factor Xa Inhibitors Sales by Country (2019-2030)

3.5.3 Europe Oral Factor Xa Inhibitors Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Oral Factor Xa Inhibitors Market Facts & Figures by Region

3.6.1 Asia Pacific Oral Factor Xa Inhibitors Market Size by Region: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Oral Factor Xa Inhibitors Sales by Region (2019-2030)

3.6.3 Asia Pacific Oral Factor Xa Inhibitors Revenue by Region (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Oral Factor Xa Inhibitors Market Facts & Figures by Country

3.7.1 Latin America Oral Factor Xa Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Oral Factor Xa Inhibitors Sales by Country (2019-2030)

3.7.3 Latin America Oral Factor Xa Inhibitors Revenue by Country

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Oral Factor Xa Inhibitors Market Facts & Figures by Country

3.8.1 Middle East and Africa Oral Factor Xa Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Oral Factor Xa Inhibitors Sales by Country (2019-2030)

3.8.3 Middle East and Africa Oral Factor Xa Inhibitors Revenue by Country

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Oral Factor Xa Inhibitors Sales by Type (2019-2030)

4.1.1 Global Oral Factor Xa Inhibitors Sales by Type (2019-2024)

4.1.2 Global Oral Factor Xa Inhibitors Sales by Type (2025-2030)

4.1.3 Global Oral Factor Xa Inhibitors Sales Market Share by Type (2019-2030)

4.2 Global Oral Factor Xa Inhibitors Revenue by Type (2019-2030)

4.2.1 Global Oral Factor Xa Inhibitors Revenue by Type (2019-2024)

4.2.2 Global Oral Factor Xa Inhibitors Revenue by Type (2025-2030)

4.2.3 Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2019-2030)

4.3 Global Oral Factor Xa Inhibitors Price by Type (2019-2030)

5 Segment by Application

5.1 Global Oral Factor Xa Inhibitors Sales by Application (2019-2030)

5.1.1 Global Oral Factor Xa Inhibitors Sales by Application (2019-2024)

5.1.2 Global Oral Factor Xa Inhibitors Sales by Application (2025-2030)

5.1.3 Global Oral Factor Xa Inhibitors Sales Market Share by Application (2019-2030)

5.2 Global Oral Factor Xa Inhibitors Revenue by Application (2019-2030)

5.2.1 Global Oral Factor Xa Inhibitors Revenue by Application (2019-2024)

5.2.2 Global Oral Factor Xa Inhibitors Revenue by Application (2025-2030)

5.2.3 Global Oral Factor Xa Inhibitors Revenue Market Share by Application (2019-2030)

5.3 Global Oral Factor Xa Inhibitors Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Pfizer

6.1.1 Pfizer Company Information

6.1.2 Pfizer Description and Business Overview

6.1.3 Pfizer Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Pfizer Oral Factor Xa Inhibitors Product Portfolio

6.1.5 Pfizer Recent Developments/Updates

6.2 Bristol Myers Squibb

6.2.1 Bristol Myers Squibb Company Information

6.2.2 Bristol Myers Squibb Description and Business Overview

6.2.3 Bristol Myers Squibb Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Bristol Myers Squibb Oral Factor Xa Inhibitors Product Portfolio

6.2.5 Bristol Myers Squibb Recent Developments/Updates

6.3 Daiichi Sankyo

6.3.1 Daiichi Sankyo Company Information

6.3.2 Daiichi Sankyo Description and Business Overview

6.3.3 Daiichi Sankyo Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Daiichi Sankyo Oral Factor Xa Inhibitors Product Portfolio

6.3.5 Daiichi Sankyo Recent Developments/Updates

6.4 Janssen Pharmaceuticals

6.4.1 Janssen Pharmaceuticals Company Information

6.4.2 Janssen Pharmaceuticals Description and Business Overview

6.4.3 Janssen Pharmaceuticals Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Janssen Pharmaceuticals Oral Factor Xa Inhibitors Product Portfolio

6.4.5 Janssen Pharmaceuticals Recent Developments/Updates

6.5 Bayer

6.5.1 Bayer Company Information

6.5.2 Bayer Description and Business Overview

6.5.3 Bayer Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Bayer Oral Factor Xa Inhibitors Product Portfolio

6.5.5 Bayer Recent Developments/Updates

6.6 Mylan

6.6.1 Mylan Company Information

6.6.2 Mylan Description and Business Overview

6.6.3 Mylan Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Mylan Oral Factor Xa Inhibitors Product Portfolio

6.6.5 Mylan Recent Developments/Updates

6.7 Zydus

6.7.1 Zydus Company Information

6.7.2 Zydus Description and Business Overview

6.7.3 Zydus Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.7.4 Zydus Oral Factor Xa Inhibitors Product Portfolio

6.7.5 Zydus Recent Developments/Updates

6.8 Lupin

6.8.1 Lupin Company Information

6.8.2 Lupin Description and Business Overview

6.8.3 Lupin Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Lupin Oral Factor Xa Inhibitors Product Portfolio

6.8.5 Lupin Recent Developments/Updates

6.9 Apotex

6.9.1 Apotex Company Information

6.9.2 Apotex Description and Business Overview

6.9.3 Apotex Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Apotex Oral Factor Xa Inhibitors Product Portfolio

6.9.5 Apotex Recent Developments/Updates

6.10 Accord Healthcare

6.10.1 Accord Healthcare Company Information

6.10.2 Accord Healthcare Description and Business Overview

6.10.3 Accord Healthcare Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Accord Healthcare Oral Factor Xa Inhibitors Product Portfolio

6.10.5 Accord Healthcare Recent Developments/Updates

6.11 Chia Tai Tianqing Pharmaceutical

6.11.1 Chia Tai Tianqing Pharmaceutical Company Information

6.11.2 Chia Tai Tianqing Pharmaceutical Description and Business Overview

6.11.3 Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio

6.11.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates

6.12 Shanghai Huilun Pharmaceutical

6.12.1 Shanghai Huilun Pharmaceutical Company Information

6.12.2 Shanghai Huilun Pharmaceutical Description and Business Overview

6.12.3 Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio

6.12.5 Shanghai Huilun Pharmaceutical Recent Developments/Updates

6.13 Qilu Pharmaceutical

6.13.1 Qilu Pharmaceutical Company Information

6.13.2 Qilu Pharmaceutical Description and Business Overview

6.13.3 Qilu Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Qilu Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio

6.13.5 Qilu Pharmaceutical Recent Developments/Updates

6.14 HEC Pharma

6.14.1 HEC Pharma Company Information

6.14.2 HEC Pharma Description and Business Overview

6.14.3 HEC Pharma Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.14.4 HEC Pharma Oral Factor Xa Inhibitors Product Portfolio

6.14.5 HEC Pharma Recent Developments/Updates

6.15 Cspc Ouyi Pharmaceutical

6.15.1 Cspc Ouyi Pharmaceutical Company Information

6.15.2 Cspc Ouyi Pharmaceutical Description and Business Overview

6.15.3 Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.15.4 Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio

6.15.5 Cspc Ouyi Pharmaceutical Recent Developments/Updates

6.16 Zhejiang Hisun Pharmaceutical

6.16.1 Zhejiang Hisun Pharmaceutical Company Information

6.16.2 Zhejiang Hisun Pharmaceutical Description and Business Overview

6.16.3 Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.16.4 Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio

6.16.5 Zhejiang Hisun Pharmaceutical Recent Developments/Updates

6.17 Hansoh Pharma

6.17.1 Hansoh Pharma Company Information

6.17.2 Hansoh Pharma Description and Business Overview

6.17.3 Hansoh Pharma Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.17.4 Hansoh Pharma Oral Factor Xa Inhibitors Product Portfolio

6.17.5 Hansoh Pharma Recent Developments/Updates

6.18 Huahai Pharmaceutical

6.18.1 Huahai Pharmaceutical Company Information

6.18.2 Huahai Pharmaceutical Description and Business Overview

6.18.3 Huahai Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.18.4 Huahai Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio

6.18.5 Huahai Pharmaceutical Recent Developments/Updates

6.19 Yangtze River Pharmaceutical

6.19.1 Yangtze River Pharmaceutical Company Information

6.19.2 Yangtze River Pharmaceutical Description and Business Overview

6.19.3 Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.19.4 Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio

6.19.5 Yangtze River Pharmaceutical Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Oral Factor Xa Inhibitors Industry Chain Analysis

7.2 Oral Factor Xa Inhibitors Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Oral Factor Xa Inhibitors Production Mode & Process

7.4 Oral Factor Xa Inhibitors Sales and Marketing

7.4.1 Oral Factor Xa Inhibitors Sales Channels

7.4.2 Oral Factor Xa Inhibitors Distributors

7.5 Oral Factor Xa Inhibitors Customers

8 Oral Factor Xa Inhibitors Market Dynamics

8.1 Oral Factor Xa Inhibitors Industry Trends

8.2 Oral Factor Xa Inhibitors Market Drivers

8.3 Oral Factor Xa Inhibitors Market Challenges

8.4 Oral Factor Xa Inhibitors Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Pfizer Inc

Bristol–Myers Squibb

Daiichi Sankyo

Janssen Pharmaceuticals

Chia Tai-Tianqing Pharmaceutical

Shanghai Huilun Pharmaceutical

Qilu Pharmaceutical

HEC Pharma

CSPC Ouyi Pharmaceutical

Zhejiang Hisun Pharmaceutical

Hansoh Pharma

Huahai Pharmaceutical

Yangtze River Pharmaceutical

List of Tables

Table 1. Global Oral Factor Xa Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Oral Factor Xa Inhibitors Market Value by Application (2024-2030) & (US$ Million)

Table 3. Global Oral Factor Xa Inhibitors Market Competitive Situation by Manufacturers in 2023

Table 4. Global Oral Factor Xa Inhibitors Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global Oral Factor Xa Inhibitors Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Oral Factor Xa Inhibitors Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Oral Factor Xa Inhibitors Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Oral Factor Xa Inhibitors Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Oral Factor Xa Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Oral Factor Xa Inhibitors, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Oral Factor Xa Inhibitors, Product Type & Application

Table 12. Global Key Manufacturers of Oral Factor Xa Inhibitors, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Oral Factor Xa Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Factor Xa Inhibitors as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Oral Factor Xa Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Oral Factor Xa Inhibitors Sales by Region (2019-2024) & (K Units)

Table 18. Global Oral Factor Xa Inhibitors Sales Market Share by Region (2019-2024)

Table 19. Global Oral Factor Xa Inhibitors Sales by Region (2025-2030) & (K Units)

Table 20. Global Oral Factor Xa Inhibitors Sales Market Share by Region (2025-2030)

Table 21. Global Oral Factor Xa Inhibitors Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Oral Factor Xa Inhibitors Revenue Market Share by Region (2019-2024)

Table 23. Global Oral Factor Xa Inhibitors Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Oral Factor Xa Inhibitors Revenue Market Share by Region (2025-2030)

Table 25. North America Oral Factor Xa Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Oral Factor Xa Inhibitors Sales by Country (2019-2024) & (K Units)

Table 27. North America Oral Factor Xa Inhibitors Sales by Country (2025-2030) & (K Units)

Table 28. North America Oral Factor Xa Inhibitors Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Oral Factor Xa Inhibitors Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Oral Factor Xa Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Oral Factor Xa Inhibitors Sales by Country (2019-2024) & (K Units)

Table 32. Europe Oral Factor Xa Inhibitors Sales by Country (2025-2030) & (K Units)

Table 33. Europe Oral Factor Xa Inhibitors Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Oral Factor Xa Inhibitors Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Oral Factor Xa Inhibitors Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Oral Factor Xa Inhibitors Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific Oral Factor Xa Inhibitors Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific Oral Factor Xa Inhibitors Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Oral Factor Xa Inhibitors Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Oral Factor Xa Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Oral Factor Xa Inhibitors Sales by Country (2019-2024) & (K Units)

Table 42. Latin America Oral Factor Xa Inhibitors Sales by Country (2025-2030) & (K Units)

Table 43. Latin America Oral Factor Xa Inhibitors Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Oral Factor Xa Inhibitors Revenue Market Share by Country (2019-2024)

Table 45. Middle East and Africa Oral Factor Xa Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East and Africa Oral Factor Xa Inhibitors Sales by Country (2019-2024) & (K Units)

Table 47. Middle East and Africa Oral Factor Xa Inhibitors Sales by Country (2025-2030) & (K Units)

Table 48. Middle East and Africa Oral Factor Xa Inhibitors Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East and Africa Oral Factor Xa Inhibitors Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Oral Factor Xa Inhibitors Sales (K Units) by Type (2019-2024)

Table 51. Global Oral Factor Xa Inhibitors Sales (K Units) by Type (2025-2030)

Table 52. Global Oral Factor Xa Inhibitors Sales Market Share by Type (2019-2024)

Table 53. Global Oral Factor Xa Inhibitors Sales Market Share by Type (2025-2030)

Table 54. Global Oral Factor Xa Inhibitors Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Oral Factor Xa Inhibitors Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2019-2024)

Table 57. Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2025-2030)

Table 58. Global Oral Factor Xa Inhibitors Price (US$/Unit) by Type (2019-2024)

Table 59. Global Oral Factor Xa Inhibitors Price (US$/Unit) by Type (2025-2030)

Table 60. Global Oral Factor Xa Inhibitors Sales (K Units) by Application (2019-2024)

Table 61. Global Oral Factor Xa Inhibitors Sales (K Units) by Application (2025-2030)

Table 62. Global Oral Factor Xa Inhibitors Sales Market Share by Application (2019-2024)

Table 63. Global Oral Factor Xa Inhibitors Sales Market Share by Application (2025-2030)

Table 64. Global Oral Factor Xa Inhibitors Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Oral Factor Xa Inhibitors Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Oral Factor Xa Inhibitors Revenue Market Share by Application (2019-2024)

Table 67. Global Oral Factor Xa Inhibitors Revenue Market Share by Application (2025-2030)

Table 68. Global Oral Factor Xa Inhibitors Price (US$/Unit) by Application (2019-2024)

Table 69. Global Oral Factor Xa Inhibitors Price (US$/Unit) by Application (2025-2030)

Table 70. Pfizer Company Information

Table 71. Pfizer Description and Business Overview

Table 72. Pfizer Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Pfizer Oral Factor Xa Inhibitors Product

Table 74. Pfizer Recent Developments/Updates

Table 75. Bristol Myers Squibb Company Information

Table 76. Bristol Myers Squibb Description and Business Overview

Table 77. Bristol Myers Squibb Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Bristol Myers Squibb Oral Factor Xa Inhibitors Product

Table 79. Bristol Myers Squibb Recent Developments/Updates

Table 80. Daiichi Sankyo Company Information

Table 81. Daiichi Sankyo Description and Business Overview

Table 82. Daiichi Sankyo Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Daiichi Sankyo Oral Factor Xa Inhibitors Product

Table 84. Daiichi Sankyo Recent Developments/Updates

Table 85. Janssen Pharmaceuticals Company Information

Table 86. Janssen Pharmaceuticals Description and Business Overview

Table 87. Janssen Pharmaceuticals Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Janssen Pharmaceuticals Oral Factor Xa Inhibitors Product

Table 89. Janssen Pharmaceuticals Recent Developments/Updates

Table 90. Bayer Company Information

Table 91. Bayer Description and Business Overview

Table 92. Bayer Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Bayer Oral Factor Xa Inhibitors Product

Table 94. Bayer Recent Developments/Updates

Table 95. Mylan Company Information

Table 96. Mylan Description and Business Overview

Table 97. Mylan Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Mylan Oral Factor Xa Inhibitors Product

Table 99. Mylan Recent Developments/Updates

Table 100. Zydus Company Information

Table 101. Zydus Description and Business Overview

Table 102. Zydus Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Zydus Oral Factor Xa Inhibitors Product

Table 104. Zydus Recent Developments/Updates

Table 105. Lupin Company Information

Table 106. Lupin Description and Business Overview

Table 107. Lupin Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Lupin Oral Factor Xa Inhibitors Product

Table 109. Lupin Recent Developments/Updates

Table 110. Apotex Company Information

Table 111. Apotex Description and Business Overview

Table 112. Apotex Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Apotex Oral Factor Xa Inhibitors Product

Table 114. Apotex Recent Developments/Updates

Table 115. Accord Healthcare Company Information

Table 116. Accord Healthcare Description and Business Overview

Table 117. Accord Healthcare Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Accord Healthcare Oral Factor Xa Inhibitors Product

Table 119. Accord Healthcare Recent Developments/Updates

Table 120. Chia Tai Tianqing Pharmaceutical Company Information

Table 121. Chia Tai Tianqing Pharmaceutical Description and Business Overview

Table 122. Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Product

Table 124. Chia Tai Tianqing Pharmaceutical Recent Developments/Updates

Table 125. Shanghai Huilun Pharmaceutical Company Information

Table 126. Shanghai Huilun Pharmaceutical Description and Business Overview

Table 127. Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 128. Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Product

Table 129. Shanghai Huilun Pharmaceutical Recent Developments/Updates

Table 130. Qilu Pharmaceutical Company Information

Table 131. Qilu Pharmaceutical Description and Business Overview

Table 132. Qilu Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 133. Qilu Pharmaceutical Oral Factor Xa Inhibitors Product

Table 134. Qilu Pharmaceutical Recent Developments/Updates

Table 135. HEC Pharma Company Information

Table 136. HEC Pharma Description and Business Overview

Table 137. HEC Pharma Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 138. HEC Pharma Oral Factor Xa Inhibitors Product

Table 139. HEC Pharma Recent Developments/Updates

Table 140. Cspc Ouyi Pharmaceutical Company Information

Table 141. Cspc Ouyi Pharmaceutical Description and Business Overview

Table 142. Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 143. Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Product

Table 144. Cspc Ouyi Pharmaceutical Recent Developments/Updates

Table 145. Zhejiang Hisun Pharmaceutical Company Information

Table 146. Zhejiang Hisun Pharmaceutical Description and Business Overview

Table 147. Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 148. Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Product

Table 149. Zhejiang Hisun Pharmaceutical Recent Developments/Updates

Table 150. Hansoh Pharma Company Information

Table 151. Hansoh Pharma Description and Business Overview

Table 152. Hansoh Pharma Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 153. Hansoh Pharma Oral Factor Xa Inhibitors Product

Table 154. Hansoh Pharma Recent Developments/Updates

Table 155. Huahai Pharmaceutical Company Information

Table 156. Huahai Pharmaceutical Description and Business Overview

Table 157. Huahai Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 158. Huahai Pharmaceutical Oral Factor Xa Inhibitors Product

Table 159. Huahai Pharmaceutical Recent Developments/Updates

Table 160. Yangtze River Pharmaceutical Company Information

Table 161. Yangtze River Pharmaceutical Description and Business Overview

Table 162. Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 163. Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Product

Table 164. Yangtze River Pharmaceutical Recent Developments/Updates

Table 165. Key Raw Materials Lists

Table 166. Raw Materials Key Suppliers Lists

Table 167. Oral Factor Xa Inhibitors Distributors List

Table 168. Oral Factor Xa Inhibitors Customers List

Table 169. Oral Factor Xa Inhibitors Market Trends

Table 170. Oral Factor Xa Inhibitors Market Drivers

Table 171. Oral Factor Xa Inhibitors Market Challenges

Table 172. Oral Factor Xa Inhibitors Market Restraints

Table 173. Research Programs/Design for This Report

Table 174. Key Data Information from Secondary Sources

Table 175. Key Data Information from Primary Sources

Table 176. Authors List of This Report

List of Figures

Figure 1. Product Picture of Oral Factor Xa Inhibitors

Figure 2. Global Oral Factor Xa Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Oral Factor Xa Inhibitors Market Share by Type: 2023 & 2030

Figure 4. Rivaroxaban Product Picture

Figure 5. Edoxaban Product Picture

Figure 6. Apixaban Product Picture

Figure 7. Global Oral Factor Xa Inhibitors Market Value by Application (2024-2030) & (US$ Million)

Figure 8. Global Oral Factor Xa Inhibitors Market Share by Application: 2023 & 2030

Figure 9. Deep Vein Thrombosis

Figure 10. Pulmonary Embolism

Figure 11. Atrial Fibrillation

Figure 12. Other

Figure 13. Global Oral Factor Xa Inhibitors Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Oral Factor Xa Inhibitors Market Size (2019-2030) & (US$ Million)

Figure 15. Global Oral Factor Xa Inhibitors Sales (2019-2030) & (K Units)

Figure 16. Global Oral Factor Xa Inhibitors Average Price (US$/Unit) & (2019-2030)

Figure 17. Oral Factor Xa Inhibitors Report Years Considered

Figure 18. Oral Factor Xa Inhibitors Sales Share by Manufacturers in 2023

Figure 19. Global Oral Factor Xa Inhibitors Revenue Share by Manufacturers in 2023

Figure 20. Global 5 and 10 Largest Oral Factor Xa Inhibitors Players: Market Share by Revenue in Oral Factor Xa Inhibitors in 2023

Figure 21. Oral Factor Xa Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 22. Global Oral Factor Xa Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 23. North America Oral Factor Xa Inhibitors Sales Market Share by Country (2019-2030)

Figure 24. North America Oral Factor Xa Inhibitors Revenue Market Share by Country (2019-2030)

Figure 25. United States Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Canada Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. Europe Oral Factor Xa Inhibitors Sales Market Share by Country (2019-2030)

Figure 28. Europe Oral Factor Xa Inhibitors Revenue Market Share by Country (2019-2030)

Figure 29. Germany Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. France Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. U.K. Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Italy Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Russia Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Asia Pacific Oral Factor Xa Inhibitors Sales Market Share by Region (2019-2030)

Figure 35. Asia Pacific Oral Factor Xa Inhibitors Revenue Market Share by Region (2019-2030)

Figure 36. China Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Japan Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. South Korea Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. India Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Australia Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. China Taiwan Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Southeast Asia Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Latin America Oral Factor Xa Inhibitors Sales Market Share by Country (2019-2030)

Figure 44. Mexico Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Brazil Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Argentina Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Colombia Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Middle East and Africa Oral Factor Xa Inhibitors Sales Market Share by Country (2019-2030)

Figure 49. Middle East and Africa Oral Factor Xa Inhibitors Revenue Market Share by Country (2019-2030)

Figure 50. Turkey Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Saudi Arabia Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. UAE Oral Factor Xa Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Global Sales Market Share of Oral Factor Xa Inhibitors by Type (2019-2030)

Figure 54. Global Revenue Market Share of Oral Factor Xa Inhibitors by Type (2019-2030)

Figure 55. Global Oral Factor Xa Inhibitors Price (US$/Unit) by Type (2019-2030)

Figure 56. Global Sales Market Share of Oral Factor Xa Inhibitors by Application (2019-2030)

Figure 57. Global Revenue Market Share of Oral Factor Xa Inhibitors by Application (2019-2030)

Figure 58. Global Oral Factor Xa Inhibitors Price (US$/Unit) by Application (2019-2030)

Figure 59. Oral Factor Xa Inhibitors Value Chain

Figure 60. Oral Factor Xa Inhibitors Production Process

Figure 61. Channels of Distribution (Direct Vs Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions